F058 How to Approach Challenges in Hidradenitis Suppurativa Management: Strategies to Optimize Use of HS Therapies
DESCRIPTION
This session will provide guidance for the management of hidradenitis suppurativa in challenging scenarios including in the setting of multiple previous treatment failures, comorbidities such as chronic infections or malignancy, or syndromic HS. Combination therapy strategies, including the potential for dual biologic or biologic plus jak inhibitor therapy will be discussed. Procedures for HS that can be done in the office, and when to reach for them, will be reviewed. Instructive cases of HS will be presented and explored in an interactive format. Practical tips and pertinent evidence from the literature will be discussed to help inform future decision-making in HS clinic visits.
LEARNING OBJECTIVES
Utilize up-to-date evidence to approach challenges in the management of hidradenitis suppurativa, addressing comorbidities, treatment selection, layering therapies, and recalcitrant disease
Identify helpful combination management strategies in HS
Describe procedures that can be performed in the outpatient setting for patients with HS
SCHEDULE
1:00 PM
My patient has milder HS: what can I offer them?
Katrina Lee, MD, FAAD
1:10 PM
Biologics and small molecule inhibitors for HS
Vivian Shi, MD, FAAD
1:25 PM
Dual biologic therapy or biologic plus JAK inhibitor therapy for HS
Jennifer Lin Hsiao, MD, FAAD
1:40 PM
HS Procedures: you can do it!
Christopher John Sayed, MD, FAAD
2:00 PM
My patient has a chronic infection or malignancy, is it safe to treat?
Steven Daniel Daveluy, MD, FAAD
2:15 PM
Comorbidity screening tips for HS
Amit Garg, MD, FAAD
2:25 PM
GLP-1 agonists for HS
Jonathan W Rick, MD, FAAD
2:35 PM
On the horizon: what's next for HS therapies?
Natalie Fragoso, MD, FAAD
2:50 PM
Q&A panel
DIRECTOR
Jennifer Lin Hsiao, MD, FAAD
CO-DIRECTOR
Vivian Shi, MD, FAAD
SPEAKERS
Steven Daniel Daveluy, MD, FAAD
Natalie Fragoso, MD, FAAD
Amit Garg, MD, FAAD
Katrina Lee, MD, FAAD
Jonathan W Rick, MD, FAAD
Christopher John Sayed, MD, FAAD
DISCLOSURES
Steven Daniel Daveluy, MD, FAAD
AbbVie – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Insmed – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Natalie Fragoso, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Acelyrin – Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Insmed Incorporated – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); Target-Derm – Investigator(Grants/Research Funding); UCB Pharma – Consultant (1099 relationship)(Fees);
Amit Garg, MD, FAAD
AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Novartis – Consultant(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Sanofi – Data Safety Monitoring Board(Fees); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Leo Pharma – Consultant (1099 relationship)(Fees); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
Katrina Lee, MD, FAAD
Incyte – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding);
Jonathan W Rick, MD, FAAD
Incyte Corporation – Consultant (1099 relationship)(Fees);
Christopher John Sayed, MD, FAAD
AbbVie – Advisory Board(Fees), Investigator(Fees), Speaker(Fees); Alumis – Consultant(Fees); AstraZeneca – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); ChemoCentryx – Investigator(Grants/Research Funding); Elasmogen – Consultant (1099 relationship)(Fees); Eli Lilly – Stockholder Public Company(Stock); Incyte – Consultant (1099 relationship)(Fees); Incyte Corporation – Investigator(Grants/Research Funding); InflaRx – Consultant(Fees), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Investigator(Fees), Speaker(Honoraria); Sandoz Pharmaceuticals AG – Consultant (1099 relationship)(Honoraria); Sanofi – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Honoraria), Consultant(Fees), Investigator(Grants/Research Funding);
Vivian Shi, MD, FAAD
AbbVie – Advisory Board(Fees), Speaker(Fees); Alumis – Advisory Board(Honoraria); Aristea Therapeutics – Advisory Board(Fees); Bain Capital – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Advisory Board(Fees); Burt's Bees – Consultant(Fees); Ceraclere – Consultant (1099 relationship)(Fees); Dematology Foundation – Other(Grants/Research Funding); Demira – Advisory Board(Fees); Dermavant Sciences, Inc. – Advisory Board(Fees); Eli Lilly and Company – Advisory Board(Fees); Foundation of Atopic Dermatitis – Other(Grants/Research Funding); Galderma – Advisory Board(Fees); Genentech, Inc. – Advisory Board(Honoraria); Global Parents for Eczema Research – Consultant(No Compensation Received); GpSkin – Consultant(Fees); HS Foundation – Board of Directors(No Compensation Received); Incyte – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); LearnHealth/LearnSkin – Other(Fees), Stockholder(Stock); Leo Pharma – Consultant (1099 relationship)(Fees); Menlo Therapeutics – Advisory Board(Fees); National Eczema Association – Consultant (1099 relationship)(Honoraria), Speaker(No Compensation Received); Novartis – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees); Polyfins, Inc – Consultant (1099 relationship)(Fees); Regeneron – Speaker(Fees); Sanofi Genzyme – Advisory Board(Fees), Speaker(Fees); Skin Actives Scientific – Other(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees); UCB Pharma – Advisory Board(Honoraria);